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JaapJan Boelens1Hurler syndrome (HS), the most severe phenotype in the spectrum of mucopolysaccharidosis type I, is
caused by a deficiency of the lysosomal enzyme alpha-L-iduronidase (IDUA). At present, hematopoietic
stem cell transplantation (HSCT) is the only treatment able to prevent disease progression in the central
nervous system, and therefore considered the treatment of choice in HS patients. Because IDUA enzyme
activities after HSCT have been suggested to influence the prognosis of HS patients, monitoring these activ-
ities after HSCT remains highly important. The use of dried blood spots (DBS) for enzyme analysis can be
a useful alternative to the conventional leukocyte assay. Importantly, this method allows for convenient
worldwide shipment, and can therefore be applied to monitor patients from larger areas of the world, or
during large-scale international studies. Furthermore, this method requires only a minimal amount of blood.
From 13 HS patients receiving HSCT, 36 paired whole blood and DBS samples were analyzed to assess
leukocyte and DBS IDUA activities, respectively. To correct for potential interfering factors, simultaneous
assay of the alpha-Galactosidase-A (AGA) activity was performed in the DBS samples and an IDUA/AGA
ratio was calculated. A strong linear correlation was demonstrated between the DBS IDUA/AGA ratio
and the leukocyte IDUA activity (r25 .875, P\.001). This correlation was applicable to all enzyme activities,
including the activities measured early after HSCTas well as heterozygous activities because of mixed chime-
rism or the use of a carrier donor. These results demonstrate that the DBS method is reliable to monitor the
biochemical effect of HSCT in HS patients.
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Hurler syndrome (HS) is the most severe pheno-
type in the spectrum of mucopolysaccharidosis type
I, an autosomal recessive inborn error of metabolism.
Because of a severe deficiency of the lysosomal enzyme
a-L-iduronidase (IDUA), HS patients suffer from
a progressive and ultimately fatal multisystem disease.
At present, hematopoietic stem cell transplantation
(HSCT) is the only treatment able to prevent deterio-
ration of the central nervous system in these patients.
Successful donor engraftment in HS patients has
shown to be highly effective, evident by an increased
life expectancy and significant improvement of
biochemical as well as clinical outcome parameters
[1]. At present, over 500 HSCTs have been performed
in HS patients worldwide, making HS the most
frequently transplanted inborn error of metabolism
and prototype for HSCT in these disorders [2,3].
The current standard for the definite diagnosis of
HS as well as the biochemical monitoring after701
Table 1. Patient Characteristics and Results
Symbol
No. of
Patients
No. of
Samples
Age at Sampling
(Months)
Median (Range)
Interval Post-HSCT
(Months)
Median (range)
DBS IDUA/AGA
Ratio
Median (Range)
Leukocyte
IDUA
Median (Range)
All patients 13 36 40.5 (12.5-96.5) 22.1 (0.4-74.8) 0.67 (0.13-1.60) 38.5 (6.5-88.0)
Unaffected/full - 11 26 43.5 (14.9-96.5) 22.2 (2.2-.59.5) 0.80 (0.36-1.60) 47.0 (19.0-88.0)
Affected/full > 1a 1 63.6 34.1 0.45 30.0
Unaffected/mixed 6 1b 3 74.0 (58.5-82.6) 66.3 (50.7-74.8) 0.20 (0.19-0.22) 11.0 (10.0-11.0)
Early post-HSCT B 5c 6 16.4 (12.5-24.6) 0.7 (0.4-0.9) 0.29 (0.13-0.48) 19.3 (6.5.39.0)
Affected/full indicates heterozygous donor/full donor chimerism; DBS, dried blood spot; early post-HSCT, samples were collected early after HSCT; No:
number, unaffected/full: unaffected donor/full donor chimerism; unaffected/mixed, unaffected donor/mixed donor chimerism.
aHLA-haploidentical mother.
bStable donor chimerism of 25%.
cAll 5 patients were transplanted using an unaffected donor and achieved full donor chimerism. Subsequent samples of these patients are represented in
the group unaffected/full.
702 Biol Blood Marrow Transplant 16:701-704, 2010M. Aldenhoven et al.HSCT is the measurement of the IDUA enzyme activ-
ity in leukocytes [4]. It has already been demonstrated
that the leukocyte enzyme activity, absent or severely
decreased before HSCT, significantly increases to
normal or heterozygous activities after HSCT. A sig-
nificantly lower leukocyte activity is observed when
a heterozygous carrier donor is used or when only
mixed chimerism is achieved [1]. Because the IDUA
enzyme activity after HSCT has been suggested to in-
fluence the prognosis of HS patients [1], monitoring
IDUA activity after HSCT is highly important.
Measuring lysosomal enzyme activities using dried
blood spots (DBS) has already been demonstrated to be
an easy method that can be a useful alternative to the
conventional leukocyte assays [5-7]. Importantly, this
method requires only a minimal amount of blood and
allows for convenient worldwide shipment, allowing
enzyme analysis from larger areas of the world and
making international comparison studies easier to1 
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Figure 1. Dried blood spot IDUA/AGA ratio versus leukocyte IDUA activity i
tation. A linear correlation is shown between the leukocyte IDUA enzyme activ
blood spot IDUA/AGA ratio (both mmol/h/L) on the vertical axis.accomplish. Whether this method is reliable to
monitor the biochemical effect of HSCT in HS
patients, however, is at present unknown.MATERIALS AND METHODS
Samples
After informed consent of the patients and families,
pairedDBS andwhole blood samples fromHSpatients
receiving HSCT at the University Medical Center
Utrecht, were collected during clinical follow-up.
HSCT donors were either unrelated donors, homozy-
gous unaffected family donors, or heterozygote family
donors. The stem cell source consisted of a bone
marrow or cord blood graft. Donor chimerism was
determined by analysis of polymorphic DNA
sequences by variable number of tandem repeats
(VNTR), as previously described [8].2 
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IDUA enzyme activity in DBS samples was mea-
sured at the University Medical Center Utrecht, as
previously described by Chamoles et al. [5]. DBS
were prepared by dispensing whole blood onto Gu-
thrie cards. Samples were collected at different medical
wards, obtained by various staff members. The DBS
were subsequently dried for at least 4 hours at room
temperature and stored at220C in a plastic bag until
analysis.
To assess the quality of the bloodspot, the lyso-
somal enzyme a-Galactosidase A (AGA), deficient in
Fabry disease, served as a control in all analyzed DBS
samples, and an IDUA/AGA ratio was calculated. All
measurements were performed in duplicate. Both
IDUA and AGA activity were expressed as mmol/h/L
blood.
Leukocyte IDUA Activity
The leukocyte IDUA enzyme activity was fluori-
metrically measured at the Erasmus University,
Rotterdam, in leukocytes isolated from peripheral
blood, as described previously [9]. Leukocyte IDUA
activity was expressed as mmol/g protein/h.
Statistical Analysis
DBS IDUA/AGA ratios were compared with
leukocyte IDUA activities using least-squares linear
regression analysis.RESULTS
Thirty-six paired whole blood and DBS samples
from 13 HS patients, receiving HSCT at the
University Medical Center Utrecht, between April
2003 and June 2009, were available for leukocyte
IDUA and DBS IDUA/AGA analysis, respectively
(Table 1). The median age at sampling was 40.5
(12.5-96.5) months, with a median interval from
HSCT until sampling of 22.1 (0.4-74.8) months.
Eleven patients were transplanted using an
unrelated-assumed to be unaffected (n 5 9) or unaf-
fected family (n 5 2) donor, and achieved full donor
chimerism. One patient was transplanted using a het-
erozygous carrier donor (HLA-haploidentical mother)
and achieved full donor chimerism, whereas in 1
patient, transplanted with an unaffected donor, a stable
donor chimerism of only 25% was achieved. In 5
patients, samples were collected shortly after HSCT,
ranging from 0.4 to 0.9 months post-HSCT. These
patients were transplanted using an unaffected donor
and achieved full donor chimerism.
As depicted in Figure 1, comparison ofDBS IDUA/
AGA ratios and leukocyte IDUA activities by linear
regression analysis confirmed a strong correlation(r25 .875,P\.001).This linear relationwas applicable
to all enzyme activities, including normal enzyme activ-
ities (depicted as-), heterozygous activities because of
the use of a carrier donor (depicted as >), or mixed
donor chimerism (depicted as 6), as well as samples
obtained early after HSCT (depicted asB).DISCUSSION AND CONCLUSION
This, to our knowledge, is the first study comparing
DBS and leukocyte assays inHSCT treated patients for
IDUA activity. A strong correlation was observed
between the leukocyte IDUA enzyme activity—the
current standard—and the DBS IDUA/AGA ratio in
HS patients receiving HSCT.
DBS samples represent a mixture of plasma and
variable types of blood cells with variable expression
of lysosomal enzymes. Importantly, the number of
leukocytes in peripheral blood can be significantly
reduced early after HSCT, considerably lowering the
absolute DBS enzyme activity. Additionally, results
can be influenced by external factors, including medi-
cation or incorrect sampling, transport, or storage [5].
To correct for these interfering factors, it is therefore
recommended to simultaneously measure the activity
of a control enzyme in the DBS, in this study AGA,
and calculate the ratio.
The use of DBS to monitor the biochemical effect
of HSCT in HS patients would offer several advan-
tages over leukocyte enzyme analysis, including (1)
lysosomal enzymes, including IDUA, have been dem-
onstrated to be highly stable in DBS for weeks at room
temperature and even months when stored at lower
temperatures [5]. This high stability allows for world-
wide shipment of DBS samples by regular mail. The
DBS method could therefore be applied to monitor
patients from larger areas of the world, lacking a spe-
cialized laboratory for enzyme analysis or during
large-scale international studies. (2) Because DBS
can be sent by mail, transportation of samples is con-
siderably less expensive and logistically more conve-
nient. (3) A significantly lower sample volume of only
a few drops is required, an advantage in cases where
obtaining larger blood samples is not convenient or
impossible.
The DBS method is already implemented at the
University Medical Center Utrecht for early diagnosis
of patients clinically suspected of having MPS I. The
continued use of DBS during the follow-up of these
patients after HSCT would therefore be a convenient
and logical option.
In conclusion, this study demonstrates that the
DBS method is reliable to monitor the biochemical
effect of HSCT in HS patients. In the near future,
the DBS method might be evaluated for monitoring
the biochemical effect of enzyme replacement therapy
704 Biol Blood Marrow Transplant 16:701-704, 2010M. Aldenhoven et al.on milder phenotypes of MPS I (Hurler-Scheie or
Scheie) and the effect of HSCT, enzyme replacement
therapy, or any future therapy (eg, gene therapy) on
other lysosomal storage disorders.ACKNOWLEDGMENTS
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